NASDAQ
4.11USD
+0.22 (+5.66%)
Dots are scored news catalysts — size = impact, color = sentiment. Tap one to read it.
Market cap
1.3B
P/E
—
EPS
—
Beta
1.09
52W range
2.23-6.51
Day range
3.85–4.15
Open
3.91
Prev close
3.89
Volume
5M
Avg volume
5.7M
Dividend
0.00
IPO
2004-07-28
https://www.fool.com/coverage/filings/2026/07/20/mannkind-evp-singh-sells-46795-shares-in-tax-driven-rsu-vesting/ · 7/20/2026-0.60
https://www.fool.com/coverage/filings/2026/07/19/is-mannkind-a-stock-to-sell-after-its-ceo-sold-363-200-shares/ · 7/20/2026+0.60
https://www.globenewswire.com/news-release/2026/06/05/3307663/29517/en/Data-at-ADA-2026-Highlights-Key-Findings-from-Clinical-and-Real-World-Studies-of-MannKind-s-Afrezza-Inhaled-Insulin-Across-Pediatric-Care-Pregnancy-and-Use-with-Automated-Insulin-D.html · 6/5/2026+0.80
https://seekingalpha.com/article/4911234-mannkind-at-an-inflexion-point-pediatric-expansion-drives-the-story-upgrade · 6/3/2026+0.90
https://seekingalpha.com/article/4910176-mannkind-corporation-mnkd-discusses-fda-approval-of-afrezza-for-pediatric-diabetes-patients · 5/29/2026+0.80
https://www.reuters.com/business/healthcare-pharmaceuticals/us-fda-approves-mannkinds-inhaled-insulin-children-2026-05-29/ · 5/29/2026+0.80
https://seekingalpha.com/article/4900413-mannkind-its-complicated · 5/7/2026-0.60
https://www.globenewswire.com/news-release/2025/09/29/3157534/29517/en/MannKind-Appoints-Dr-Ajay-Ahuja-as-Executive-Vice-President-and-Chief-Medical-Officer.html · 9/29/2025+0.30
https://seekingalpha.com/article/4819910-mannkind-corporation-mnkd-presents-at-wells-fargo-20th-annual-healthcare-conference-2025 · 9/8/2025+0.50
https://seekingalpha.com/article/4820099-mannkind-corporation-mnkd-presents-at-cantor-global-healthcare-conference-2025-transcript · 9/8/2025+0.00
https://www.businesswire.com/news/home/20250825799079/en/SCPH-Stock-Alert-Halper-Sadeh-LLC-Is-Investigating-Whether-the-Sale-of-scPharmaceuticals-Inc.-Is-Fair-to-Shareholders/ · 8/25/2025+0.00
https://www.globenewswire.com/news-release/2025/08/25/3138369/29517/en/MannKind-to-Acquire-scPharmaceuticals-Accelerating-Revenue-Growth-and-Emerging-as-a-Patient-Centric-Leader-in-Cardiometabolic-and-Lung-Diseases.html · 8/25/2025+0.80
MannKind Corporation operates as a biopharmaceutical firm, primarily focused on innovating and bringing to market respiratory-delivered treatments. Its efforts are directed towards tackling endocrine system disorders and rare lung conditions within the U.S. market. The company's key product is Afrezza, an inhaled insulin designed to improve glycemic control for adults managing diabetes. MannKind also actively markets Thyquidity, promoting it to adult and pediatric endocrinologists and other healthcare professionals for the treatment of hypothyroidism. In terms of collaborations, MannKind holds a strategic licensing and partnership agreement with United Therapeutics Corporation. Furthermore, it is collaborating with NRx Pharmaceuticals to develop a dry powder formulation of ZYESAMI (aviptadil), which is a synthetic variant of human vasoactive intestinal peptide intended to shield cells from inflammatory processes. Established in 1991, MannKind Corporation's corporate offices are located in Westlake Village, California.
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
